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Lineage 2 West Nile virus (WNV) strains are endemic in South Africa and cause severe 
neurological disease in horses. An inactivated lineage 1 vaccine, Duvaxyn WNV, protects 
mice  against  challenge  with  a  neuroinvasive  South  African  lineage  2  strain  of  WNV.  To 
evaluate the potential of Duvaxyn WNV to protect horses against lineage 2 strains of WNV, 
serum neutralising antibody responses of horses against lineage 1 WNV strain NY385/99 
and lineage 2 WNV strain SPU93/01, isolated from a human with meningo-encephalitis in 
South Africa, were compared following vaccination with two doses of Duvaxyn WNV, 28 
days apart, and a third dose one year later. Twenty-two seronegative horses were randomly 
assigned to two treatment groups: 16 to a vaccinated group and six retained as unvaccinated 
controls. Blood samples were taken from all horses on study days 0, 28, 35, 42, 49, 91, 141, 182, 
231, 274, 322, 364 and 413. Primovaccination with Duvaxyn WNV resulted in high titres of 
serum neutralising antibodies against both strains. Following a single dose of Duvaxyn WNV 
on day 399, one year after primovaccination, there was a strong anamnestic response with a 
log25-fold rise in the titres of neutralising antibodies against strains NY385/99 and SPU93/01. 
These results provide further evidence that Duvaxyn WNV is likely to protect horses against 
infection with lineage 2 strains of WNV and that a single annual booster may be sufficient to 
maintain immunity against lineage 2 WNV infection in horses.
Introduction
There are two major genetic lineages of West Nile virus (WNV): lineage 1, which is found in 
North America, North Africa, Europe and Australia, and lineage 2, which is endemic in central 
and southern Africa (Burt et al. 2002). Several minor lineages, including lineages 3–5 and possibly 
6, occur in India, Eastern Europe and Spain (Bakonyi et al. 2005; Bondre et al. 2007; Vázquez et 
al. 2010). Initially, WNV was not thought to be a significant pathogen of horses in South Africa 
as few clinical cases were reported (Guthrie et al. 2003; Lanciotti et al. 2002). However, lineage 2 
WNV infections have increasingly been associated with encephalitis in horses in South Africa 
(Venter et al. 2009). An 18-month pilot study of neurological disease in horses identified WNV 
infection in 19% of cases; all cases presented with severe neurological disease, of which 85% had 
to be euthanased or died with signs of encephalitis (Venter et al. 2009). All cases with a positive 
reverse transcriptase polymerase chain reaction were shown to be infected with lineage 2 WNV by 
DNA sequencing and phylogenetic analysis (Venter et al. 2009); clinical signs resembled those of 
lineage 1 WNV infections in the USA, such as ataxia, weakness, recumbency, muscle fasciculation 
and high case fatality rates (Dauphin et al. 2004; Durand, Simon & Tolou 2004; Schuler et al. 2004; 
Venter et al. 2009; Ward et al. 2004).
Vaccines  to  protect  horses  against  WNV  infection  include  a  canarypox–WNV  recombinant 
vaccine expressing prM and E genes from lineage 1 WNV strain NY385/99 (Minke et al. 2011), 
an inactivated lineage 1 WNV vaccine and a DNA vaccine (Dauphin & Zientara 2007). There are 
very limited data regarding the efficacy of these vaccines against lineage 2 WNV infection in 
horses. A recent study of a canarypox–WNV recombinant vaccine demonstrated efficacy against 
a European lineage 2 strain of WNV (Minke et al. 2011), but licensing of vaccines containing 
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genetically modified organisms is problematic. An inactivated 
lineage 1 WNV vaccine, Duvaxyn WNV, has been shown to 
effectively protect mice against infection with a South African 
neuroinvasive strain of lineage 2 WNV (Venter et al. 2013). 
The present study examined the serum neutralising antibody 
response of seronegative horses against lineage 1 and lineage 
2 WNV following vaccination with Duvaxyn WNV.
Materials and methods
Animals and study design
All 22 horses enrolled in the study were screened for the 
presence of IgG antibodies against WNV using a commercial 
enzyme-linked  immunosorbent  assay  (ELISA)  kit,  ID 
Screen West Nile Competition ELISA (ID VET Innovative 
Diagnostics, Montpellier, France), 16 and 10 days before the 
day the study commenced (day 0). Of the 22 seronegative 
horses enrolled, 16 were assigned to the vaccinated group 
(T02) and six were retained as unvaccinated controls (T01). 
Horses in group T02 were vaccinated with Duvaxyn WNV 
on days 0, 28 and 399. Duvaxyn WNV was administered by 
deep intramuscular injection. One horse may have received 
an incomplete dose on day 399. Blood samples were taken 
from all horses on days 0, 28, 35, 42, 49, 91, 141, 182, 231, 
274, 322, 364 and 413 and tested for the presence of serum 
neutralising  antibodies  against  lineage  1  WNV  strain 
NY385/99, which had been isolated from a dead bird in the 
USA in 1999 (Venter et al. 2005), and lineage 2 WNV strain 
SPU93/01, which had been isolated from a human patient 
with encephalitis in South Africa in 2001 (Venter et al. 2009).
Serum neutralisation tests
Testing  for  serum  neutralising  antibodies  against  lineages 
1 and 2 WNV was conducted at the National Institute for 
Communicable  Diseases  (National  Health  Laboratory 
Service, South Africa) in accordance with a modification of 
the OIE manual using TCID50 serum neutralisation assays. 
Duplicates  of  serial  two-fold  dilutions  of  sera  inactivated 
at 56 °C for 30 min were tested using a microneutralisation 
procedure (Swanepoel et al. 1986), with the slight modification 
of using WNV isolate NY385/99 representing lineage 1 and 
WNV  isolate  SPU93/01  representing  lineage  2  to  assess 
neutralising  antibodies  against  the  two  lineages.  Vero 
cells were cultivated in Eagles Minimal Essential Medium 
(BioWhitaker,  MD,  USA)  containing  L-glutamine,  non-
essential amino acids, antibiotics (100 IU penicillin, 100 µg 
streptomycin and 0.25 µg amphotericin B, per mL) and 10% 
foetal bovine serum (Gibco), and incubated at 37 °C in 5% 
CO2. Virus stocks comprised supernatant fluids from Vero 
cell cultures infected with the aforementioned WNV isolates. 
Inactivated sera were serially diluted two-fold from a 1:10 
dilution in 50 µL medium in 96-well flat-bottom cell culture 
microplates. Equal volumes of virus suspension, containing 
a calculated 100 TCID50 of virus, were added to each well and 
incubated for 60 min at 37 °C in 5% CO2 before plates were 
seeded with 2 × 104 cells per well in 100 µL medium. The 
plates, with loose lids, were incubated at 37 °C in 5% CO2 
and the results were read after 10 days. Titres were expressed 
as the reciprocal of the serum dilution that inhibited ≥ 75% 
of viral cytopathic effect. A serum sample was considered 
positive when it had a titre ≥ log10 1.0, equivalent to a serum 
dilution ≥ 1:10.
Statistics
Data were analysed using SAS v. 9.2.3 (SAS Institute, Cary, 
North Carolina). Serum neutralisation titres were analysed 
using  a  linear  mixed  model  with  repeated  measures. 
Titres reported as < 10 were adjusted to five for analysis. 
Titres  were  natural  log  transformed  before  analysis.  Test 
virus  lineage,  treatment  (i.e.  vaccination  or  control),  day, 
lineage  ×  treatment  interaction,  lineage  ×  day  interaction, 
treatment × day interaction and lineage × treatment × day 
3-way  interaction  were  entered  as  fixed  effects.  Animal 
and residual were entered as random effects. Since lineage, 
treatment, lineage × treatment interaction and treatment × 
day interaction were all significant at the 0.05 level, treatment 
comparisons were conducted within each lineage and day. 
Similarly, lineage comparisons were conducted within each 
treatment and day.
Ethical considerations
This study was approved by the National Health Laboratory 
Service  Animal  Ethics  Committee  and  the  Pfizer  Animal 
Health Ethical Review Assessment Committee.
Results
One horse in the vaccinated group was sold and withdrawn 
from the study on day 280 and one unvaccinated horse was 
sold and withdrawn from the study on day 341.
Back-transformed least-squares geometric mean (BT-LSGM) 
titres of serum neutralising antibodies against lineage 1 and 
lineage 2 WNV are shown in Figure 1. The effect of WNV test 
strain was significant (p = 0.0112) and there were significant 
effects of treatment (p < 0.0001), time (p < 0.0001), treatment × 
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FIGURE  1:  Back-transformed  least-squares  geometric  mean  titres  of  serum 
neutralising antibody against West Nile virus strains NY385/99 (lineage 1) and 
SPU93/01 (lineage 2), by treatment group and virus strain.
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time interaction (p < 0.0001) and WNV test strain × treatment 
interaction  (p  =  0.0112)  on  titres  of  serum  neutralising 
antibodies.
There  were  significant  pairwise  differences  in  BT-LSGM 
serum  neutralising  antibody  titres  against  lineage  1 
WNV  strain  NY385/99  between  unvaccinated  (T01)  and 
vaccinated (T02) horses at all sampling points from day 28 
to day 413 (p < 0.0307 in all cases). After day 0, BT-LSGM 
titres  of  serum  neutralising  antibodies  against  strain 
NY385/99  were  consistently  higher  in  vaccinated  horses 
than in unvaccinated controls at all sampling points. There 
were  significant  pairwise  differences  in  BT-LSGM  serum 
neutralising  antibody  titres  against  lineage  2  WNV  strain 
SPU93/01  between  unvaccinated  (T01)  and  vaccinated 
(T02) horses at all sampling points from day 35 to day 413 
(p < 0.0028 in all cases), except on day 322. BT-LSGM titres of 
serum neutralising antibodies against strain SPU93/01 were 
consistently higher in vaccinated horses than in unvaccinated 
controls at all sampling points after day 35.
With the exception of day 322, serum neutralising antibody 
titres against both strain NY385/99 and strain SPU93/01 were 
< 10 in all unvaccinated horses. On day 322, the test result 
for one unvaccinated horse indicated a serum neutralising 
antibody titre of 160 against both strain NY385/99 and strain 
SPU93/01. However, at all other samplings this horse had a 
titre < 10 against both strains.
In  vaccinated  horses,  there  were  significant  pairwise 
differences in BT-LSGM serum neutralising antibody titres 
against strain NY385/99 compared with strain SPU93/01 at 
all sampling points from day 49 to day 413 (p < 0.0163 in all 
cases). After day 49, BT-LSGM titres of serum neutralising 
antibodies against strain NY385/99 were consistently higher 
than against strain SPU93/01 at all tested time points.
From day 49 to day 364, BT-LSGM neutralising titres against 
strain NY385/99 were two to three times higher than those 
against strain SPU93/01. On day 413, compared with day 
364, the BT-LSGM neutralising titre against strain NY385/99 
was 47 times higher, and against strain SPU93/01 it was 40 
times higher.
Discussion
These results demonstrate that vaccination of horses with 
commercial  Duvaxyn  WNV  stimulates  the  production 
of  high  titres  of  serum  neutralising  antibodies  against 
a  neuroinvasive  South  African  lineage  2  WNV  strain. 
Following  primovaccination  with  two  doses  of  Duvaxyn 
WNV four weeks apart, the peak and subsequent titres of 
serum neutralising antibodies against WNV strain SPU93/01 
were  lower  than  for  lineage  1  WNV  strain  NY385/99, 
but  the  response  following  the  second  administration 
of  Duvaxyn  WNV  and  the  subsequent  decline  in  serum 
neutralising  antibodies  against  lineage  2  strain  SPU93/01 
were comparable to the pattern seen for serum neutralising 
antibodies against lineage 1 WNV strain NY385/99.
Following a single dose of Duvaxyn WNV on day 399, one 
year after primovaccination, there was a strong anamnestic 
response  with  a  large  rise  in  the  titres  of  neutralising 
antibodies against both lineage 1 WNV strain NY385/99 and 
lineage 2 WNV strain SPU93/01 to values well above their 
peak following primovaccination.
Duvaxyn WNV was shown to protect mice against challenge 
with a neuroinvasive South African lineage 2 strain of WNV 
(Venter et al. 2013). These results provide further evidence 
that  Duvaxyn  WNV  is  likely  to  protect  horses  against 
infection with lineage 2 strains of WNV and that a single 
annual  booster  may  be  sufficient  to  maintain  immunity 
against lineage 2 WNV infection in horses.
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